Investigating heart-related side effects in children with relapsed acute myeloid leukemia
Official title: Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications
Funded at University of Pennsylvania · NIH-10887480 · Data updated 2026-11-12
This study is looking at how heart problems can affect kids who have had a relapse of acute myeloid leukemia after their chemotherapy, so we can better understand and manage these side effects during their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $676,727 |
| NIH project number | 5R01HL164925-03 |
| Project ID | NIH-10887480 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who have been diagnosed with relapsed acute myeloid leukemia.
✕Less likely to help
Patients who are not diagnosed with acute myeloid leukemia or who are older than 11 years may not receive benefits from this research.
What this research studies
This research focuses on understanding the heart-related side effects that can occur in children who have relapsed from acute myeloid leukemia (AML) after undergoing intensive chemotherapy. It aims to gather comprehensive data on the occurrence and progression of cardiotoxicity throughout the treatment process, rather than just during initial therapy. By analyzing the experiences of these patients, the research seeks to identify patterns and risks associated with different treatment protocols. This information will help improve the management of cardiotoxicity in pediatric AML patients.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and management strategies for heart-related side effects in children undergoing treatment for relapsed AML.
How similar studies have gone: Previous research has shown that understanding treatment-related side effects can significantly improve patient care, indicating that this approach has the potential for success.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Getz, Kelly Diringer — University of Pennsylvania
- Study coordinator: Getz, Kelly Diringer
Related research
Other NIH-funded projects on the same topics.
-
Cardiotoxicity in kids with relapsed AML and what it means for their hearts
A study tracking how chemotherapy for relapsed pediatric AML affects heart health over time and what that means for long-term wellbeing.
-
Understanding Heart Problems from Chemotherapy in Children with Relapsed Leukemia
This project aims to better understand how chemotherapy for relapsed acute myeloid leukemia (AML) affects the hearts of children and adolescents.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.